These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 4703126)

  • 1. Scheduling of arabinosylcytosine and 6-thioguanine therapy.
    LePage GA; White SC
    Cancer Res; 1973 May; 33(5):946-9. PubMed ID: 4703126
    [No Abstract]   [Full Text] [Related]  

  • 2. Disposition of arabinosylcytosine (NSC-63878) and 6-THIOGUANINE (NSC-752) in solid L1210 leukemia tumor-bearing mice.
    Pittillo RF; Woolley C
    Cancer Chemother Rep; 1973; 57(3):275-89. PubMed ID: 4201593
    [No Abstract]   [Full Text] [Related]  

  • 3. Biochemical mechanisms for the synergism between 6-thioguanine and 6-(methylmercapto)purine ribonucleoside in sarcoma 180 cells.
    Nelson JA; Parks RE
    Cancer Res; 1972 Oct; 32(10):2034-41. PubMed ID: 4673141
    [No Abstract]   [Full Text] [Related]  

  • 4. Biochemical aspects of drug combinations.
    Brockman RW
    Cancer Chemother Rep 2; 1974 Mar; 4(1):115-29. PubMed ID: 4135108
    [No Abstract]   [Full Text] [Related]  

  • 5. Effect of drug combination of antitumor activity and myelotoxicity.
    Fujimoto S; Inouye T; Tsukagoshi S
    Gan; 1976 Apr; 67(2):207-14. PubMed ID: 964553
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Manipulation of DNA synthesis in normal and neoplastic tissues with drugs.
    LePage GA
    Adv Enzyme Regul; 1974; 12():373-81. PubMed ID: 4462385
    [No Abstract]   [Full Text] [Related]  

  • 7. Combination therapy: some concepts and results.
    Skipper HE
    Cancer Chemother Rep 2; 1974 Mar; 4(1):137-45. PubMed ID: 4363649
    [No Abstract]   [Full Text] [Related]  

  • 8. Lack of activity of beta-2'-deoxythioguanosine against two tumors resistant to 6-thioguanine.
    Nelson JA; Kuhns JN; Carpenter JW
    Cancer Res; 1975 May; 35(5):1372-4. PubMed ID: 1168098
    [No Abstract]   [Full Text] [Related]  

  • 9. Peroral therapy with cytosine arabinoside. Preliminary laboratory and clinical findings.
    Goldenberg DM; Schricker KT; von der Emde J; Sögtrop HH
    Arzneimittelforschung; 1968 Jun; 18(6):712-4. PubMed ID: 5755808
    [No Abstract]   [Full Text] [Related]  

  • 10. Studies on drug resistance. V. Combination chemotherapy with cytosine arabinoside (NSC-63878) plus 6-thioguanine (NSC-752) in cytosine arabinoside-sensitive and -resistant P815 mouse neoplasms.
    Kreis W
    Cancer Chemother Rep; 1973; 57(3):349-51. PubMed ID: 4751259
    [No Abstract]   [Full Text] [Related]  

  • 11. Effective means of reducing toxicity without concomitant sacrifice of efficacy of carcinostatic therapy.
    LePage GA; Kaneko T
    Cancer Res; 1969 Dec; 29(12):2314-8. PubMed ID: 5387263
    [No Abstract]   [Full Text] [Related]  

  • 12. Studies on beta-D-xylofuranosyl-6-thioguanine in mice.
    Kaneko T; LePage GA
    Cancer Res; 1970 Mar; 30(3):699-701. PubMed ID: 5425292
    [No Abstract]   [Full Text] [Related]  

  • 13. Hypothetical mechanism of therapeutic synergism induced by the combination of 6-thioguanine and 3-[(4-amino-2-methyl-5-pyrimidinyl)methyl]-1-(2-chloroethyl)-1-nitrosourea hydrochloride.
    Fujimoto S; Ogawa M; Sakurai Y
    Cancer Res; 1982 Oct; 42(10):4079-85. PubMed ID: 6955008
    [No Abstract]   [Full Text] [Related]  

  • 14. Reduction of colony-forming cell sensitivity to arabinosylcytosine by halothane anesthesia.
    Bruce DL; Lin HS; Bruce WR
    Cancer Res; 1970 Jun; 30(6):1803-5. PubMed ID: 5457942
    [No Abstract]   [Full Text] [Related]  

  • 15. Leukaemic subclones in chronic myelogenous leukaemia. Differences in drug sensitivity and in differentiation capacity.
    Pedersen B; Killmann SA
    Acta Med Scand; 1971; 190(1-2):61-9. PubMed ID: 5317797
    [No Abstract]   [Full Text] [Related]  

  • 16. Basis of observed resistance of L1210 leukemia in mice: methotrexate, 6-thioguanine, 6-methylmercaptopurine riboside, 6-mercaptopurine, 5-fluorouracil, and 1-beta-D-arabinofuranosylcytosine administered in different combinations.
    Kim K; Blechman WJ; Riddle VG; Pardee AB
    Cancer Res; 1981 Nov; 41(11 Pt 1):4529-34. PubMed ID: 7198006
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacology of 6-thioguanine in man.
    LePage GA; Whitecar JP
    Cancer Res; 1971 Nov; 31(11):1627-31. PubMed ID: 5287342
    [No Abstract]   [Full Text] [Related]  

  • 18. Treatment of acute myeloblastic leukemia.
    Clarkson BD; Dowling MD; Gee TS; Burchenal JH
    Bibl Haematol; 1973; 39():1098-114. PubMed ID: 4521515
    [No Abstract]   [Full Text] [Related]  

  • 19. Combination chemotherapy involving alpha-difluoromethylornithine and 1-beta-D-arabinofuranosylcytosine in murine L1210 leukemia.
    Prakash NJ; Sunkara PS
    Cancer Res; 1983 Jul; 43(7):3192-6. PubMed ID: 6406054
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of combination chemotherapy in vivo and in culture with l- -D-arabinofuranosylcytosine and 1-formylisoquinoline thiosemicarbazone.
    Grindey GB; Mihich E; Nichol CA
    Cancer Res; 1972 Mar; 32(3):522-6. PubMed ID: 5061306
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.